Large molecules, such as antibodies, peptides and related structures, represent a promising class of biomolecules, which are being used as efficient biomolecular tools, forming the basis of highly effective therapeutics.
In 2017, one fourth of all drugs on the market were protein-based therapeutics treating chronic diseases such as cancer, diabetes, autoimmune diseases, rare genetic diseases, and others.
CF Plus Chemicals offers first-in-class, complementary hypervalent-iodine based bioconjugation technologies which allow for a straightforward modification of antibodies, peptides and other protein structures to uncover their full potential, improve their biological activity and increase their therapeutic index.
We have been in particular devoted to apply our unique technologies to advance the development of Antibody Drug Conjugates, antibodies conjugated to toxic substances, which is a rapidly growing class of targeted biotherapeutics.
The novel technology has been demonstrated to conjugate small functional groups (up to 1000 Da) specifically to selected amino acids depending on the choice of protocol. In contrast to the conventional maleimide-based technology, our technology offers a highly stable peptide/antibody conjugation strategy which enables to control the overall amount of payload and lead to design of a safer next generation ADCs for immunooncology.
Furthermore, our technology allows not only to conjugate various biorthogonal functional groups to large proteins in a site selective manner but it can be equally used to selectively install biorthogonal handles to existing natural product-based toxins.
Our technology therefore constitutes a one-stop-shop technology which allows both bioconjugation of proteins as well as ample possibilities for optimization of warhead attachment strategy, thus streamlining the ADC discovery process on both key sides.
Facilitates a controlled site-specific conjugation
Straightforward application leading to a cost-effective, high yielding conjugation
Improved stability in comparison to maleimide conjugation
Discovered, validated and patented at ETH Zurich